Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 343

1.

Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.

Karimiani EG, Marriage F, Merritt AJ, Burthem J, Byers RJ, Day PJ.

Exp Hematol. 2014 Mar;42(3):183-191.e5. doi: 10.1016/j.exphem.2013.11.006. Epub 2013 Nov 20.

PMID:
24269846
2.

Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.

Lee J, Shen P, Zhang G, Wu X, Zhang X.

Biomed Pharmacother. 2013 Mar;67(2):157-63. doi: 10.1016/j.biopha.2012.10.017. Epub 2012 Nov 19.

PMID:
23201011
3.

Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.

Xu XH, Gan YC, Xu GB, Chen T, Zhou H, Tang JF, Gu Y, Xu F, Xie YY, Zhao XY, Xu RZ.

J Zhejiang Univ Sci B. 2012 Nov;13(11):867-74. doi: 10.1631/jzus.B1200021.

4.

Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.

Liao HF, Su YC, Zheng ZY, Jhih Cai C, Hou MH, Chao KS, Chen YJ.

Biomed Pharmacother. 2012 Jul;66(5):378-83. doi: 10.1016/j.biopha.2011.12.008. Epub 2012 Feb 16.

PMID:
22397755
5.

MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.

Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O, Granot G.

Cancer Lett. 2015 Jan 28;356(2 Pt B):597-605. doi: 10.1016/j.canlet.2014.10.006. Epub 2014 Oct 8.

PMID:
25305453
6.

PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.

Wu N, Kurosu T, Oshikawa G, Nagao T, Miura O.

Int J Oncol. 2013 Feb;42(2):419-28. doi: 10.3892/ijo.2012.1729. Epub 2012 Dec 6.

7.

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.

Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA, White DL, Hughes TP.

Leuk Lymphoma. 2011 Nov;52(11):2139-47. doi: 10.3109/10428194.2011.591013. Epub 2011 Jun 30.

PMID:
21718141
8.

ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.

Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):47-55. doi: 10.1016/j.bcmd.2014.02.008. Epub 2014 Mar 11. Erratum in: Blood Cells Mol Dis. 2015 Dec;55(4):420.

PMID:
24629639
9.

Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.

Wu LX, Wu Y, Chen RJ, Liu Y, Huang LS, Lou LG, Zheng ZH, Chen YZ, Xu JH.

Acta Pharmacol Sin. 2014 Mar;35(3):401-9. doi: 10.1038/aps.2013.180. Epub 2014 Feb 3.

10.
11.

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.

Blood. 2005 Apr 15;105(8):3303-11. Epub 2004 Dec 30.

12.

Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.

Borgo C, Cesaro L, Salizzato V, Ruzzene M, Massimino ML, Pinna LA, Donella-Deana A.

Mol Oncol. 2013 Dec;7(6):1103-15. doi: 10.1016/j.molonc.2013.08.006. Epub 2013 Aug 22.

13.
14.
15.
16.

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.

Blood. 2004 Oct 15;104(8):2532-9. Epub 2004 Jul 15.

17.

Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.

Lee YL, Chen CW, Liu FH, Huang YW, Huang HM.

PLoS One. 2013 Apr 17;8(4):e61939. doi: 10.1371/journal.pone.0061939. Print 2013.

18.

BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.

Xu C, Fu H, Gao L, Wang L, Wang W, Li J, Li Y, Dou L, Gao X, Luo X, Jing Y, Chim CS, Zheng X, Yu L.

Oncogene. 2014 Jan 2;33(1):44-54. doi: 10.1038/onc.2012.557. Epub 2012 Dec 3.

PMID:
23208504
19.

Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.

Nambu T, Araki N, Nakagawa A, Kuniyasu A, Kawaguchi T, Hamada A, Saito H.

Cancer Sci. 2010 Jan;101(1):137-42. doi: 10.1111/j.1349-7006.2009.01365.x. Epub 2009 Sep 14.

20.

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.

Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, Talpaz M, Donato NJ.

Blood. 2008 Apr 1;111(7):3821-9. doi: 10.1182/blood-2007-08-109330. Epub 2008 Jan 30.

Supplemental Content

Support Center